Adana A.M. Llanos, PhD, MPH

home / authors / adana-a-m-llanos-phd-mph

Articles

Adana A.M. Llanos, PhD, MPH

Dr Llanos on Prediagnositic Allostatic Load and Breast Cancer Clinicopathology in Black Women

Adana A.M. Llanos, PhD, MPH
April 25th 2023

Adana A.M. Llanos, PhD, MPH, discusses the relationship between prediagnostic allostatic load and breast cancer clinicopathology in Black women.

Read More

Adana A.M. Llanos, PhD, MPH

Dr. Llanos on the Role of Social and Biological Determinants on Cancer Risk

Adana A.M. Llanos, PhD, MPH
October 20th 2022

Adana A.M. Llanos, PhD, MPH, discusses the role of social and biological determinants on cancer risk.

Read More

Adana A.M. Llanos, PhD, MPH

Dr. Llanos on Genetic Disparities in Cancer Care

Adana A.M. Llanos, PhD, MPH
September 21st 2022

Adana A.M. Llanos, PhD, MPH, discusses disparities in genetic research in cancer care.

Read More

Adana A.M. Llanos, PhD, MPH

Dr. Llanos on Recognizing Social Determinants of Disparities in Cancer Care

Adana A.M. Llanos, PhD, MPH
June 16th 2022

Adana A.M. Llanos, PhD, MPH, discusses how to recognize social determinants of disparities in cancer care.

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data